Intravenous immunoglobulins for the treatment of mild to moderate Alzheimer’s disease: a phase II randomised double-blind placebo-controlled dose-finding trial

摘要

BackgroundThree small trials have suggested effects of intravenous immunoglobulins (IVIG) on biomarkers and symptoms of mild-to-moderate Alzheimer’s disease (AD). We explored the safety, the effective dose, and the infusion interval for Octagam^®10% in this patients’ group.